Objective To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6-17, and >= 18 years old, treated in a real-world setting. Methods Patients with DS were treated with fenfluramine in the European Union Early Access Program (EAP)
An Examination of the Efficacy and Safety of Fenfluramine in Adults, Children, and Adolescents with Dravet Syndrome in a Real-World Practice Setting: A report from the Fenfluramine European Early Access Program / Renzo Guerrini , Nicola Specchio , Ángel Aledo-Serrano , Milka Pringsheim , Francesca Darra , Thomas Mayer , Antonio Gil-Nagel , Tilman Polster , Sameer M Zuberi , Amélie Lothe , Arnold Gammaitoni , Adam Strzelczyk. - In: EPILEPSIA OPEN. - ISSN 2470-9239. - ELETTRONICO. - (2022), pp. 0-0. [10.1002/epi4.12624]
An Examination of the Efficacy and Safety of Fenfluramine in Adults, Children, and Adolescents with Dravet Syndrome in a Real-World Practice Setting: A report from the Fenfluramine European Early Access Program
Renzo Guerrini;
2022
Abstract
Objective To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6-17, and >= 18 years old, treated in a real-world setting. Methods Patients with DS were treated with fenfluramine in the European Union Early Access Program (EAP)
| File | Dimensione | Formato | |
|---|---|---|---|
|
Epilepsia Open - 2022 - Guerrini - An examination of the efficacy and safety of fenfluramine in adults children and.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
1.6 MB
Formato
Adobe PDF
|
1.6 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
